THTemplateLibG1Q4KB7DK4jpgjpg – The Hindu


Heart of hearts: Carmat, the designer and developer of “the world’s most advanced total artificial heart project”, has announced the certification of its new manufacturing site at Boisd’Arcy, near Paris, France. The project aims to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure. The automated site will allow the production of up to 800 units per year at full capacity and will make use of new technology and tools such as robots to help assemble some of the parts of the prostheses. The site will also have a fully-automated software station. The device uses the latest advancements in material sciences, biology, electronics and medicine to mimic the actions of the heart. The first transplant was carried out in 2013. The company, which has the backing of the European Commission, estimates that patients in the U.S. and Europe could benefit from its artificial heart, a market worth more than €16 billion or $22 billion. Picture shows the auto-regulating, bioprosthetic device. AFP/BERTRAND GUAY BERTRAND GUAY

Heart of hearts: Carmat, the designer and developer of “the world’s most advanced total artificial heart project”, has announced the certification of its new manufacturing site at Boisd’Arcy, near Paris, France. The project aims to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure. The automated site will allow the production of up to 800 units per year at full capacity and will make use of new technology and tools such as robots to help assemble some of the parts of the prostheses. The site will also have a fully-automated software station. The device uses the latest advancements in material sciences, biology, electronics and medicine to mimic the actions of the heart. The first transplant was carried out in 2013. The company, which has the backing of the European Commission, estimates that patients in the U.S. and Europe could benefit from its artificial heart, a market worth more than €16 billion or $22 billion. Picture shows the auto-regulating, bioprosthetic device. AFP/BERTRAND GUAY BERTRAND GUAY
 



more-in

‘,
nextArrow: ”,
responsive: [
breakpoint: 1599,
settings:
slidesToShow: 3

]
});
});




Source link Google News

Add Comment